AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25041227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure everolimus
Number of subjects: 115
Study 25041227 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 115
Study 22093233 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU at 47 J/cm²
Number of subjects: 141
Study 22093233 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU at 52 J/cm²
Number of subjects: 141
Study 22093233 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU at 59 J/cm²
Number of subjects: 141
Study 22093233 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups combined
Number of subjects: 141
Study 19606455 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM) by a trained occupational therapist for 4 months
Number of subjects: 102
Study 19606455 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (Control group)
Number of subjects: 102
Study 19606455 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 102
Study 22299599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/levonorgestrel combined oral contraceptive (20 µg ethinylestradiol/100 µg levonorgestrel) for 21 days
Number of subjects: 34
Study 15662209 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 341
Study 12424652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and adaptive training of working memory (WM) tasks
Number of subjects: 0
Study 10751841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acne treatments
Number of subjects: 0
Study 8759897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (IFN alpha)
Number of subjects: 99
Study 8759897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFN alpha)
Number of subjects: 99
Study 8759897 — intervention group
Group type: COMPARATOR
Intervention: Low-risk observation group
Number of subjects: 99
Study 8759897 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival (OS) for IFN alpha group
Number of subjects: 99
Study 8759897 — intervention group
Group type: COMPARATOR
Intervention: Overall Survival (OS) for control group
Number of subjects: 99
Study 8759897 — intervention group
Group type: COMPARATOR
Intervention: Overall Survival (OS) for low-risk group
Number of subjects: 99
Study 2007888 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy
Number of subjects: 32
Study 2007888 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist interventions
Number of subjects: 32
Study 2007888 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 32
Study 7096960 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate 2 g/day for 4 weeks
Number of subjects: 24
Study 7096960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7096960 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate
Number of subjects: 24
Study 29428536 — intervention group
Group type: COMPARATOR
Intervention: Foam Sclerotherapy (FS) alone
Number of subjects: 182
Study 29428536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation after Foam Sclerotherapy (FSL)
Number of subjects: 182
Study 27038920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg every 8 hours for 7 days or until shock reversal
Number of subjects: 50
Study 27038920 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 8 hours for 7 days or until shock reversal
Number of subjects: 50
Study 27038920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg
Number of subjects: 50
Study 27038920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27038920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg in patients with baseline cortisol < 15 ug/dL
Number of subjects: 50
Study 27038920 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with baseline cortisol < 15 ug/dL
Number of subjects: 50
Study 25712437 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical tacrolimus (Tcr)
Number of subjects: 30
Study 25712437 — intervention group
Group type: COMPARATOR
Intervention: 1% cyclosporine A (Cyc)
Number of subjects: 30
Study 24403197 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (nephrologist, nurse, psychologist, social worker)
Number of subjects: 40
Study 24403197 — intervention group
Group type: COMPARATOR
Intervention: Routine team (nephrologist and nurse)
Number of subjects: 40
Study 24403197 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team
Number of subjects: 40
Study 20395952 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity curriculum on controllable reasons for obesity (diet/exercise)
Number of subjects: 159
Study 20395952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prejudice reduction condition presenting evidence on uncontrollable reasons for obesity (genes/environment)
Number of subjects: 159
Study 20395952 — intervention group
Group type: COMPARATOR
Intervention: Neutral curriculum focusing on alcohol use in young people
Number of subjects: 159
Study 17891547 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus music imagery (twice weekly for up to eight sessions)
Number of subjects: 78
Study 17891547 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 78
Study 16173852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group therapy (CT)
Number of subjects: 187
Study 16173852 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (including continuation of pharmacotherapy)
Number of subjects: 187
Study 12502654 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nutrition and exercise intervention (11 weekly nutrition classes, triweekly walking groups)
Number of subjects: 75
Study 12502654 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic diabetes education only)
Number of subjects: 75
Study 10374096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 23
Study 10374096 — intervention group
Group type: COMPARATOR
Intervention: In-vitro fertilization (IVF)
Number of subjects: 23
Study 8911161 — intervention group
Group type: EXPERIMENTAL
Intervention: HASTE MR urography
Number of subjects: 56
Study 1650266 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine + cisplatin
Number of subjects: 46
Study 1650266 — intervention group
Group type: COMPARATOR
Intervention: best supportive care
Number of subjects: 46
Study 7081117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE)
Number of subjects: 10
Study 28982740 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 22.5 mg
Number of subjects: 265
Study 28982740 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 75 mg
Number of subjects: 265
Study 28982740 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 225 mg
Number of subjects: 265
Study 28982740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 28982740 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659
Number of subjects: 265
Study 26991464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology combined with HPV16/18 genotyping
Number of subjects: 520
Study 26991464 — intervention group
Group type: COMPARATOR
Intervention: Cytology with a threshold of ASC-US
Number of subjects: 520
Study 25102847 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and school-based events incorporating an animated film, skits, and public pledging ceremonies.
Number of subjects: 14
Study 25102847 — intervention group
Group type: COMPARATOR
Intervention: Shortened version of the intervention (received by control villages before the final follow-up round).
Number of subjects: 14
Study 22785143 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 27
Study 22785143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 20031284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's iodine group
Number of subjects: 100
Study 20031284 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 100
Study 18696359 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring
Number of subjects: 57
Study 15522899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate 125 mg infused over 1 h
Number of subjects: 8
Study 15522899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate 250 mg infused over 2 h
Number of subjects: 8
Study 15522899 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) pre-treatment
Number of subjects: 8
Study 15522899 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-treatment
Number of subjects: 8
Study 12413432 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella-zoster hyperimmune globulin (VZV-IG) 2mL/kg body weight
Number of subjects: 40
Study 12413432 — intervention group
Group type: COMPARATOR
Intervention: Human albumin 5% 2mL/kg body weight (Control group)
Number of subjects: 40
Study 12413432 — intervention group
Group type: COMPARATOR
Intervention: McGill Pain-Rating Questionnaire
Number of subjects: 40
Study 12413432 — intervention group
Group type: COMPARATOR
Intervention: Revised Multidimensional Pain Scale (RMSS)
Number of subjects: 40
Study 12413432 — intervention group
Group type: COMPARATOR
Intervention: Freiburg symptom list (FBL)
Number of subjects: 40
Study 10220271 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateletpheresis using AMICUS
Number of subjects: 26
Study 10220271 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateletpheresis using MCS 3p
Number of subjects: 26
Study 10220271 — intervention group
Group type: COMPARATOR
Intervention: Infusion of ACD-A
Number of subjects: 26
Study 10220271 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study 8521710 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 710
Study 8521710 — intervention group
Group type: COMPARATOR
Intervention: Lippes Loop IUD
Number of subjects: 710
Study 2196353 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 4 mg/kg in two divided doses on alternate days orally for 8 days
Number of subjects: 11
Study 2196353 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 11
Study 357451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-controlled relaxation therapy
Number of subjects: 28
Study 357451 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 357451 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study 30136879 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (Bounce Back Now - BBN)
Number of subjects: 979
Study 31536511 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 700 mg
Number of subjects: 78
Study 31536511 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg
Number of subjects: 78
Study 31536511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 27175783 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed conditions (certain outcome)
Number of subjects: 1300
Study 27175783 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed conditions (uncertain outcome)
Number of subjects: 1300
Study 26046796 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus erlotinib
Number of subjects: 88
Study 26046796 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 88
Study 24093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein (VLDL) cholesterol level
Number of subjects: 35
Study 24093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol proportions in large VLDLs (Fraction 4)
Number of subjects: 35
Study 24093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol proportions in large VLDLs (Fraction 5)
Number of subjects: 35
Study 24093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol proportions in medium VLDL (Fraction 6)
Number of subjects: 35
Study 24093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of VLDL particles
Number of subjects: 35
Study 21855758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 59
Study 21855758 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 59
Study 19675477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrated (HYR)
Number of subjects: 17
Study 19675477 — intervention group
Group type: COMPARATOR
Intervention: Dehydrated (DHR)
Number of subjects: 17
Study 17960967 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (N = 6)
Number of subjects: 11
Study 17960967 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (N = 5)
Number of subjects: 11
Study 15483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy including cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, hormonal synchronization with conjugated estrogens and tamoxifen, followed by definitive radiotherapy or mastectomy and adjuvant chemotherapy.
Number of subjects: 107
Study 15483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy for stage IIIA breast cancer patients.
Number of subjects: 107
Study 15483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy for stage IIIB non-IBC patients.
Number of subjects: 107
Study 15483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy for IBC patients.
Number of subjects: 107
Study 15483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic response in stage IIIA or IBC patients.
Number of subjects: 107
Study 15483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of dermal lymphatic invasion in clinical IBC patients.
Number of subjects: 107
Study 11157314 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid (1 g fat/kg body wt)
Number of subjects: 16
Study 11157314 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (1 g fat/kg body wt)
Number of subjects: 16
Study 11157314 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fatty acids (1 g fat/kg body wt)
Number of subjects: 16
Study 9436720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (mean dose: 477 units)
Number of subjects: 73
Study 9436720 — intervention group
Group type: COMPARATOR
Intervention: Botox (mean dose: 152 units)
Number of subjects: 73
Study 9436720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 73
Study 9436720 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 73
Study 8615058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha, 24 dihydroxyvitamin D3 ointment (4 micrograms/g applied once daily) for 8 weeks
Number of subjects: 20
Study 8615058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8615058 — intervention group
Group type: COMPARATOR
Intervention: 1 alpha, 24 dihydroxyvitamin D3 ointment and Placebo
Number of subjects: 20
Study 2653461 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and cyclosporine (n = 43)
Number of subjects: 93
Study 2653461 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine alone (n = 50)
Number of subjects: 93
Study 788750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prorenoate potassium (40 mg)
Number of subjects: 6
Study 788750 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg)
Number of subjects: 6
Study 788750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31617739 — intervention group
Group type: EXPERIMENTAL
Intervention: Water deprivation (WD)
Number of subjects: 35
Study 31617739 — intervention group
Group type: COMPARATOR
Intervention: Euhydration control condition (CON)
Number of subjects: 35
Study 31064967 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement program for behavioral skills in postpartum care
Number of subjects: 43
Study 31064967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 28167176 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Roll Group (FMG)
Number of subjects: 38
Study 28167176 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group (PG)
Number of subjects: 38
Study 28167176 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38
Study 25998877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready for Child program
Number of subjects: 1193
Study 25998877 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1193
Study 24102851 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous blood pressure measurement
Number of subjects: 240
Study 24102851 — intervention group
Group type: COMPARATOR
Intervention: Sequential blood pressure measurement
Number of subjects: 240
Study 21211729 — intervention group
Group type: EXPERIMENTAL
Intervention: leuproreline 11,25 mg for 3 years
Number of subjects: 264
Study 21211729 — intervention group
Group type: COMPARATOR
Intervention: radiotherapy plus leuproreline 11,25 mg for 3 years
Number of subjects: 264
Study 19925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 17
Study 19925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (70.4 IU/kg)
Number of subjects: 17
Study 19925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (78.6 IU/kg)
Number of subjects: 17
Study 16936950 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with amniotic membrane (study group)
Number of subjects: 32
Study 16936950 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy without amniotic membrane (control group)
Number of subjects: 32
Study 14609603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stenting
Number of subjects: 412
Study 14609603 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherectomy before stenting
Number of subjects: 412
Study 10356097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 74
Study 10356097 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 74
Study 8832603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20
Study 8832603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVB
Number of subjects: 186
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg TNB
Number of subjects: 186
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg TNB followed by 1 mg TNB at 60 min
Number of subjects: 186
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg TNB followed by 0.5 mg TNB at 60 min
Number of subjects: 186
Study 2006593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg TNB (divided into 2 doses)
Number of subjects: 186
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of TNB and IVB
Number of subjects: 186
Study 2006593 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study 7082535 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg) i.v.
Number of subjects: 6
Study 7082535 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v.
Number of subjects: 6
Study 6330773 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency/low intensity (HiF/Lol) TENS for 30 minutes
Number of subjects: 31
Study 6330773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency/high density (LoF/Hil) TENS for 30 minutes
Number of subjects: 31
Study 6330773 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (placebo)
Number of subjects: 31
Study 29171086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary prourokinase (IP)
Number of subjects: 230
Study 29171086 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 230
Study 25810068 — intervention group
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa treatment
Number of subjects: 4038
Study 24885192 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients or their caregivers
Number of subjects: 345
Study 23257490 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (8 mg Lycored TM per day in two divided doses of 4 mg each)
Number of subjects: 92
Study 23257490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo tablet twice a day)
Number of subjects: 92
Study 20967981 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1 intramuscular injection)
Number of subjects: 96
Study 20967981 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (on-demand monotherapy for 6 weeks)
Number of subjects: 96
Study 20967981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (testosterone undecanoate and vardenafil in the same doses and duration)
Number of subjects: 96
Study 18369200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus 1: maximal eucapnic voluntary hyperpnea against inspiratory resistance
Number of subjects: 12
Study 18369200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus 2: Pet(CO(2)) 6.1 mm Hg above resting with ventilation restriction
Number of subjects: 12
Study 18369200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus 3: Pet(CO(2)) 7.7 mm Hg above resting with further ventilation restriction
Number of subjects: 12
Study 15857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in patients with generalized aggressive periodontitis (GAgP)
Number of subjects: 39
Study 15857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in patients with generalized chronic periodontitis (GCP)
Number of subjects: 39
Study 15857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in periodontally healthy patients
Number of subjects: 39
Study 15857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth and implants in patients with generalized aggressive periodontitis (GAgP)
Number of subjects: 39